TARGETING HEALTHY LONGEVITY
Break the silos and take the moonshot for healthy longevity for all
WHAT IS METABESITY?
Metabesity is a constellation of chronic diseases of aging (including diabetes, obesity, cardiovascular and neurodegenerative diseases, cancer, and the aging process itself) that have common metabolic roots and may be delayed or prevented through common solutions. Dr. Alexander Fleming first coined the phrase, now more widely used among geoscientists, educators, and the press, to denote that emerging geroscience holds out the prospect of preventing or delaying chronic diseases by delaying or even reversing biological aging through targeting the Pan-Condition of Metabesity, which underlines most conditions of age in age decline.
The Kitalys Institute produces the Targeting Healthy Longevity Conferences (Formerly Targeting Metabesity) in its mission to break down professional silos and publicize the translation of emerging geroscience among multiple stakeholders.
Targeting Healthy Longevity 2023
Loneliness: The Hidden Public Health Crisis
Tuesday, October 17, 2023
11 a.m. to 12:30 p.m. EDT.
The Targeting Metabesity 2022 conference took on one of the greatest healthcare challenges and opportunities of the 21st century: the prevention or delay of chronic diseases to achieve healthy longevity for all. This complex objective now appears achievable based on developments in geroscience in recent decades that suggest we may be able to delay, or even reverse, biological aging. This cross-disciplinary conference addresses the abundant opportunities for achieving equitable healthspan and the remaining challenges for converting discoveries into products for the general population.
The Targeting Metabesity 2021 conference will further take on one of the greatest healthcare challenges and opportunities of the 21st century: the prevention or delay of chronic diseases to achieve healthy longevity for all. This complex objective now appears achievable based on developments in geroscience in recent decades that suggest we may be able to delay, or even reverse, biological aging. Join us in October 11-14, 2021 both virtually and live in Washington, DC for an even more innovative and cross-disciplinary conference that addresses the abundant opportunities for achieving equitable healthspan and the remaining challenges for converting discoveries into products for the general population.
Targeting Metabesity 2020, held virtually due to the COVID-19 pandemic in October 2020, was broadcast live from Harpers Ferry, WV, and attracted about 1,000 registrants worldwide, with 80 speakers over four days. In addition to the usual stellar collection of scientists, doctors, and representatives of large and emerging companies and capital markets, speakers included the President of the National Academy of Medicine, the Scientific Director of the National Institute on Aging, the Director of the FDA Office of New Drugs, two members of Congress, a member of the U.K. House of Lords Chair of the U.K. All-Party Parliamentary Group for Longevity, Strategic Advisory Group, and several best-selling authors. Also, a new Day 4 was dedicated to an Emerging Company Showcase that featured corporate presentations by two dozen hot emerging 'metabolic' companies, with breakout sessions.
The second Metabesity conference, called by Margaretta Colangelo of Deep Knowledge Ventures "one of the most important longevity conferences of the year," was held in Washington, DC in 2019, with a stellar speakers roster that included Richard Hodes, Director of the National Institute on Aging, Gary Gibbons, Director of the National Heart, Lung and Blood Institute, Janet Woodcock, Director of the Center for Drug Evaluation and Research at FDA, Susan Mayne, Director of the Center for Food Safety and Applied Nutrition at FDA, and leaders from geroscience, diabetes, cancer, nutrition, exercise, large and emerging companies, connectivity and loneliness, longevity venture capitalists and other stakeholders.
Together with Professor Lawrence Steinman, former long-time head of the immunology department at Stanford and co-discoverer of the M.S. drug Tysabri, Dr. Fleming organized the inaugural Targeting Metabesity conference in London in 2017. This conference brought together what Alex Zhavoronkov, CEO of A.I. leader, Insilco Medicine, characterized in Forbes as a "staggering" set of speakers, including Oxford professors on the boards of Roche and the Novo Nordisk Foundation, Chair of the Nobel Assembly that selects the Nobel Prize for Medicine or Physiology, Deputy Chief Executive of UK NICE, CEO of the Buck Institute for Research on Aging, and CMO of the CMS under the Obama Administration.